Adds nitazene to schedule I of controlled substances.
Impact
The addition of nitazene to Schedule I will significantly impact the legal framework surrounding controlled substances in New York. It aligns the state's regulations with growing concerns over the rising usage and associated risks of nitazene, particularly in the context of the ongoing opioid crisis. This change will enhance restrictions on the possession, distribution, and manufacturing of nitazene, making it illegal without specific authorization.
Summary
Bill S09187 proposes to amend the Public Health Law in New York by adding nitazene to Schedule I of controlled substances. This classification indicates that nitazene, a synthetic opioid, is deemed to have a high potential for abuse and is not accepted for medical use, thus placing it under stringent regulatory restrictions.
Contention
While the bill may be viewed favorably by those advocating for stricter controls on illicit drug use, it could face opposition from stakeholders concerned about its potential impact on legitimate medical practices and research. There might be apprehensions regarding its overreach into areas where the use of similar substances may be warranted for pain management or other medical purposes. The discussion around the bill could reflect divergent perspectives on public health priorities versus the need for medical autonomy.
Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.
Directs the commissioner of the office of alcoholism and substance abuse services to establish a program for individuals to receive free drug test strips to detect the presence of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants; directs the commissioner of the office of alcoholism and substance abuse services, in cooperation with the commissioner of the department of health, to develop and conduct a public awareness and educational campaign on the dangers of medetomidine, benzodiazepine, nitazenes, and/or other harmful contaminants.
Requires practitioners to discuss certain risks with a patient who is being prescribed a schedule II controlled substance or an opioid analgesic; requires the department of health to develop practitioner guidelines.
Authorizes the imposition of bail for certain offenses involving the sale or possession with intent to sell of a controlled substance or a synthetic opioid.